Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX1305 for Optic Nerve Damage from Open-Angle Glaucoma (Phase IIb)
CTR20260267Phase 2Active
- Sponsor
- Jiangsu Zhongxin Pharmaceutical
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SMR001 in open-angle glaucoma (OAG), Glaucoma, sponsored by Jiangsu Zhongxin Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
SMR001
03
Conditions
open-angle glaucoma (OAG)Glaucoma
Beyond the preview
Go deeper on CTR20260267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260267.